Open Pyeloplasty Versus Laparoscopic Pyeloplasty: A Single Centre Prospective Study

注册号:

Registration number:

ChiCTR2000034469 

最近更新日期:

Date of Last Refreshed on:

2020-07-06 03:05:49 

注册时间:

Date of Registration:

2020-07-05 00:00:00 

注册号状态:

补注册

Registration Status:

Retrospective registration

注册题目:

Open Pyeloplasty Versus Laparoscopic Pyeloplasty: A Single Centre Prospective Study

Public title:

Open Pyeloplasty Versus Laparoscopic Pyeloplasty: A Single Centre Prospective Study

注册题目简写:

English Acronym:

研究课题的正式科学名称:

Patient Reported OutcomesOpen Pyeloplasty Versus Laparoscopic Pyeloplasty: A Single Centre Prospective Study

Scientific title:

Patient Reported OutcomesOpen Pyeloplasty Versus Laparoscopic Pyeloplasty: A Single Centre Prospective Study

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

Muhammad Tahir 

研究负责人:

Omer Farooq Rehman 

Applicant:

Muhammad Tahir 

Study leader:

Omer Farooq Rehman 

申请注册联系人电话:

Applicant telephone:

+92 33 32343828

研究负责人电话:

Study leader's
telephone:

+44 743 47145373

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

doctor.muhammad.tahir@gmail.com

研究负责人电子邮件:

Study leader's E-mail:

farooq.rehman@live.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

Jinnah Postgraduate Medical Centre

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

DHA Phase 7

研究负责人通讯地址:

Maqsood Medical Centre, Peshawar

Applicant address:

DHA Phase 7

Study leader's address:

Maqsood Medical Centre, Peshawar

申请注册联系人邮政编码:

Applicant postcode:

75500

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

巴基斯坦卡拉齐真纳教学医学中心研究生医学中心

Applicant's institution:

Jinnah Postgraduate Medical Centre

研究负责人所在单位:

巴基斯坦白沙瓦玛克苏德医学中心

Affiliation of the Leader:

Maqsood Medical Centre, Peshawar

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

UROMMC124/16/08/2016

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

IRB

Name of the ethic committee:

Institutional Review Board

伦理委员会批准日期:

Date of approved by ethic committee:

2016-08-16 00:00:00

伦理委员会联系人:

IRB

Contact Name of the ethic committee:

Institutional Review Board

伦理委员会联系地址:

巴基斯坦卡拉齐真纳教学医学中心

Contact Address of the ethic committee:

Jinnah Postgraduate Medical Centre, Karachi, Pakistan

伦理委员会联系人电话:

Contact phone of the ethic committee:

+92 33 32101231

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

ATTA UR RAHMAN

Primary sponsor:

ATTA UR RAHMAN

研究实施负责(组长)单位地址:

巴基斯坦白沙瓦玛克苏德医学中心

Primary sponsor's address:

Maqsood Medical Centre, Peshawar, Pakistan

试验主办单位(项目批准或申办者):

Secondary sponsor:

经费或物资来源:

Nil

Source(s) of funding:

Nil

研究疾病:

uretropelvic obstruction  

Target disease:

uretropelvic obstruction

研究疾病代码:

Target disease code:

研究类型:

干预性研究

Study type:

Interventional study

研究所处阶段:

其它 

Study phase:

N/A

研究设计:

病例对照研究 

Study design:

Case-Control study 

研究目的:

The aim of the study was to compare the clinical outcomes and patient satisfaction rates among open pyeloplasty and laparoscopic pyeloplasty groups.  

Objectives of Study:

The aim of the study was to compare the clinical outcomes and patient satisfaction rates among open pyeloplasty and laparoscopic pyeloplasty groups.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

Inclusion criteria

排除标准:

Whereas Patients with reflux disease, single functioning kidney, duplex system, differential function <20%, previously operated PUJO or the presence of renal stones were excluded from the study.

Exclusion criteria:

Whereas Patients with reflux disease, single functioning kidney, duplex system, differential function <20%, previously operated PUJO or the presence of renal stones were excluded from the study.

研究实施时间:

Study execute time:

From 2015-01-03 00:00:00 To 2017-12-29 00:00:00  

征募观察对象时间:

Recruiting time:

From 2015-01-03 00:00:00 To 2016-12-28 00:00:00

干预措施:

Interventions:

组别:

1

样本量:

32

Group:

1

Sample size:

干预措施:

Open pyeloplasty

干预措施代码:

Intervention:

Open pyeloplasty

Intervention code:

组别:

2

样本量:

30

Group:

2

Sample size:

干预措施:

laproscopic pyeloplasty

干预措施代码:

Intervention:

laproscopic pyeloplasty

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

巴基斯坦

省(直辖市):

卡拉齐 

市(区县):

白沙瓦 

Country:

Pakistan

Province:

KPK

City:

Peshawar

单位(医院):

Maqsood Medical Centre 

单位级别:

三级 

Institution
hospital:

Maqsood Medical Centre

Level of the institution:

Tertiary

测量指标:

Outcomes:

指标中文名:

SF-12

指标类型:

主要指标

Outcome:

SF-12

Type:

Primary indicator

测量时间点:

1 year

测量方法:

Measure time point of outcome:

1 year

Measure method:

指标中文名:

VAS

指标类型:

次要指标

Outcome:

VAS

Type:

Secondary indicator

测量时间点:

24 hours

测量方法:

Measure time point of outcome:

24 hours

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

Stone

组织:

Ureter

Sample Name:

Stone

Tissue:

Ureter

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

征募研究对象情况:

Recruiting status:

结束

/Completed

年龄范围:

Participant age:

最小 Min age 18 years
最大 Max age 60 years

性别:

男性

Gender:

Male

随机方法(请说明由何人用什么方法产生随机序列):

N/A

Randomization Procedure (please state who generates the random number sequence and by what method):

N/A

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

不公开/Private

盲法:

N/A

Blinding:

N/A

是否共享原始数据:

IPD sharing

是Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

private message only

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

private message only

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

SPSS

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

SPSS

数据与安全监察委员会:

Data and Safety Monitoring Committee:

有/Yes

注册人:

Name of Registration:

 2020-07-06 03:05:49